First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies

被引：0

作者：

Ang, J. E. ^{[1
]}

Hauns, B. ^{[2
]}

Mais, A. ^{[2
]}

Parker, A. ^{[1
]}

Lal, R. ^{[1
]}

Olmos, D. ^{[1
]}

Mollenhauer, M. ^{[2
]}

Walz, A. ^{[2
]}

de Bono, J. S. ^{[1
]}

机构：

[1] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England

[2] Nycomed GmbH, Exploratory Clin Dev, Constance, Germany

来源：

EJC SUPPLEMENTS | 2008年 / 6卷 / 12期

关键词：

D O I：

10.1016/S1359-6349(08)72327-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：123 / 124

页数：2

共 50 条

[41] A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies. [J].

Giles, FJ ;

Fischer, T ;

Cortes, J ;

Beck, J ;

Ravandi-Kashani, F ;

Garcia-Manero, G ;

Kantarjian, HM ;

Peng, B ;

Rae, PE ;

Laird, G ;

Sharma, S ;

Dugan, M ;

Albitar, M ;

Bhalla, KM .

BLOOD, 2004, 104 (11) :499A-499A

[42] Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922). [J].

Ramalingam, S. ;

Parise, R. A. ;

Egorin, M. J. ;

Argiris, A. ;

Stoller, R. ;

Beattie, L. ;

Aparicio, A. ;

Newman, E. M. ;

Zwiebel, J. ;

Belani, C. P. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :98S-98S

[43] PFK-158, first-in-man and first-in-class inhibitor of PFKFB3/glycolysis: A phase I, dose escalation, multi-center study in patients with advanced solid malignancies [J].

Redman, Rebecca ;

Pohlmann, Paula ;

Kurman, Michael ;

Tapolsky, Gilles H. ;

Chesney, Jason .

CANCER RESEARCH, 2015, 75

[44] Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS) [J].

Garcia-Manero, G ;

Issa, JP ;

Cortes, J ;

Koller, C ;

O'brien, S ;

Estey, E ;

Canalli, AA ;

Chiao, J ;

Richon, V ;

Kantarjian, H .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :201S-201S

[45] Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours [J].

A R A Razak ;

S J Hotte ;

L L Siu ;

E X Chen ;

H W Hirte ;

J Powers ;

W Walsh ;

L-A Stayner ;

A Laughlin ;

V Novotny-Diermayr ;

J Zhu ;

E A Eisenhauer .

British Journal of Cancer, 2011, 104 :756-762

[46] Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors [J].

Siu, Lillian L. ;

Hotte, Sebastien J. ;

Chen, Eric X. ;

Hirte, Hal W. ;

Powers, Jean ;

Stayner, Lee-Anne ;

Lacobucci, Anne ;

Novotny-Diermayr, Veronica ;

Zhu, Joy ;

Eisenhauer, Elizabeth A. .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)

[47] Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours [J].

Razak, A. R. A. ;

Hotte, S. J. ;

Siu, L. L. ;

Chen, E. X. ;

Hirte, H. W. ;

Powers, J. ;

Walsh, W. ;

Stayner, L-A ;

Laughlin, A. ;

Novotny-Diermayr, V. ;

Zhu, J. ;

Eisenhauer, E. A. .

BRITISH JOURNAL OF CANCER, 2011, 104 (05) :756-762

[48] A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors [J].

Ngamphaiboon, Nuttapong ;

Dy, Grace K. ;

Ma, Wen Wee ;

Zhao, Yujie ;

Reungwetwattana, Thanyanan ;

DePaolo, Dawn ;

Ding, Yi ;

Brady, William ;

Fetterly, Gerald ;

Adjei, Alex A. .

INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) :225-232

[49] A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma [J].

A Rocca ;

S Minucci ;

G Tosti ;

D Croci ;

F Contegno ;

M Ballarini ;

F Nolè ;

E Munzone ;

A Salmaggi ;

A Goldhirsch ;

P G Pelicci ;

A Testori .

British Journal of Cancer, 2009, 100 :28-36

[50] A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors [J].

Nuttapong Ngamphaiboon ;

Grace K. Dy ;

Wen Wee Ma ;

Yujie Zhao ;

Thanyanan Reungwetwattana ;

Dawn DePaolo ;

Yi Ding ;

William Brady ;

Gerald Fetterly ;

Alex A. Adjei .

Investigational New Drugs, 2015, 33 :225-232

← 1 2 3 4 5 →